Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assays

// Alan Eastman 1 1 Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA Correspondence to: Alan Eastman, email: // Keywords : cytotoxicity assays, cell survival, apoptosis, target validation, synergy Received : July 05, 2016 Accepted : October 12, 2016 Published : October 14, 2016 Abstract The high failure rate of anticancer drug discovery and development has consumed billions of dollars annually. While many explanations have been provided, I believe that misinformation arising from inappropriate cell-based screens has been completely over-looked. Most cell culture experiments are irrelevant to how drugs are subsequently administered to patients. Usually, drug development focuses on growth inhibition rather than cell killing. Drugs are selected based on continuous incubation of cells, then frequently administered to the patient as a bolus. Target identification and validation is often performed by gene suppression that inevitably mimics continuous target inhibition. Drug concentrations in vitro frequently far exceed in vivo concentrations. Studies of drug synergy are performed at sub-optimal concentrations. And the focus on a limited number of cell lines can misrepresent the potential efficacy in a patient population. The intent of this review is to encourage more appropriate experimental design and data interpretation, and to improve drug development in the area of cell-based assays. Application of these principles should greatly enhance the successful translation of novel drugs to the patient.